Efficacy of high versus conventional dose of ergocalciferol supplementation on serum 25‐hydroxyvitamin D and interleukin‐6 levels among hemodialysis patients with vitamin D deficiency: A multicenter, randomized, controlled study. Issue 2 (17th August 2021)

• Record Type: Journal Article
• Authors: Nata, Naowanit; Siricheepchaiyan, Wittaya; Supasyndh, Ouppatham; Satirapoj, Bancha
• Is Part Of: Therapeutic apheresis and dialysis. Volume 26:Issue 2(2022)
• Page Start: 378
• Page End: 386
• Publication Date: 2021-08-17
• Subjects: end stage renal disease -- ergocalciferol -- hemodialysis -- inflammation -- vitamin D deficiency; Hemapheresis -- Periodicals; Dialysis -- Periodicals; Blood Component Removal -- Periodicals; Renal Dialysis -- Periodicals; Hémaphérèse -- Périodiques; Dialyse -- Périodiques; Sang -- Collecte et conservation -- Périodiques; 616
• DOI: 10.1111/1744-9987.13722
• Languages: English
• ISSNs: 1744-9979

Abstract

Abstract: Long‐term dialysis involves a chronic inflammatory state and produces a high prevalence of vitamin D deficiency. A clinical trial was conducted in hemodialysis with serum 25‐hydroxyvitamin D (25[OH]D) level <30 ng/ml. The conventional‐group ( N = 35) and the high‐dose group ( N = 35) were treated with ergocalciferol according to the K/DOQI guidelines and double dosage of ergocalciferol from the recommendation for 8 weeks, respectively. The main outcomes were measured by serum 25[OH]D and interleukin‐6 (IL‐6). At the end of 8 weeks, a statistically significant greater increase was observed of mean serum 25[OH]D levels and a decrease of mean parathyroid hormone levels in the high‐dose group compared with the conventional‐dose group. The high dose group had the higher achievement of vitamin D sufficiency than the conventional‐dose group (97.4% vs. 76.4%, p = 0.012). No significant difference was found in mean changes of serum IL‐6 level in both groups, except subgroup patients with vitamin D deficiency or serum 25[OH]D <20 ng/ml, high dose treatment suppressed serum IL‐6 level (−2.67 pg/ml [IQR −6.56 to −0.17], p = 0.039). No differences were observed between the two groups in adverse events. Oral high‐dose ergocalciferol supplementation has achieved higher vitamin D sufficiency than standard dose in end stage renal disease patients on dialysis.